Led by the China Pituitary Adenoma Specialist Council, the Chinese Consensus for the Diagnosis and Treatment of Acromegaly (2021 Edition) is developed combined with the research progress of pituitary growth hormone (GH)-secreting adenoma both at home and abroad, evidence-based evidence of the diagnosis and treatment of acromegaly, and China's national conditions. Based on the guideline for acromegaly (2013 Edition), the new version of consensus emphasizes the importance of multidisciplinary team (MDT) and individual therapy. The criteria for control of acromegaly is discussed. Pathological criteria for the diagnosis of pituitary GH-secreting adenoma is updated. New developments in surgery, drug and radiotherapy are introduced. Meanwhile, the diagnosis and treatment of acromegaly patients concurrent with other particular scenarios, including pregnancy and refractory pituitary GH-secreting adenoma is suggested. This article aims to describe the updated key points of the new version of the consensus, and thus facilitate the clinical implementation of standardized diagnosis and treatment for acromegaly patients.
由中国垂体腺瘤协作组牵头，结合国内外垂体生长激素腺瘤研究进展、肢端肥大症诊治的循证证据和我国国情，组织相关专家共同编写《中国肢端肥大症诊治共识（2021版）》。新版共识在2013版指南基础上，强调多学科诊疗模式（MDT）和个体化诊治理念，讨论了肢端肥大症的治疗目标设定，更新了垂体生长激素腺瘤的病理诊断标准，介绍了手术、药物、放射治疗中的新进展，对肢端肥大症合并妊娠、难治性垂体生长激素腺瘤等特殊患者的诊治提出建议。本文就新版共识的更新要点进行阐述，为临床医师开展合理的规范化诊疗提供依据和帮助。.